Khalid Jazieh Selected Research

tipifarnib (R115777)

1/2019

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Khalid Jazieh Research Topics

Disease

5	Neoplasms (Cancer) 03/2024 - 01/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2021
1	Melanoma (Melanoma, Malignant) 05/2024
1	Breast Neoplasms (Breast Cancer) 07/2020

Drug/Important Bio-Agent (IBA)

3	durvalumabIBA 01/2022 - 07/2021
2	Immune Checkpoint InhibitorsIBA 03/2024 - 07/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2022
1	NivolumabIBA 05/2024
1	IpilimumabIBA 05/2024
1	Epidermal Growth Factor (EGF)IBA 01/2019
1	Farnesyltranstransferase (Farnesyltransferase)IBA 01/2019
1	tipifarnib (R115777)IBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019

Therapy/Procedure

3	Immunotherapy 05/2024 - 01/2022
3	Therapeutics 01/2022 - 07/2020
1	Chemoradiotherapy 01/2022
1	Cardiopulmonary Resuscitation (CPR) 01/2020